Difference between revisions of "Talk:Ancillary testing in prostate cancer"
Jump to navigation
Jump to search
(Created page with "MSI testing - in BRCA1/2: {{cite journal |vauthors=Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R...") |
(No difference)
|
Revision as of 15:17, 1 November 2022
MSI testing - in BRCA1/2: "Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA". J Immunother Cancer 8 (2). August 2020. doi:10.1136/jitc-2020-001065. PMC 7422632. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422632/.